Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:06 pm Sale | 2025-09-30 | 13G | VYNE Therapeutics Inc. VYNE | Citadel Advisors LLC | 3,732 0.000% | -1,096,597 (-99.66%) | Filing History |
| 2025-11-14 3:23 pm Sale | 2025-09-30 | 13G | VYNE Therapeutics Inc. VYNE | Eventide Asset Management, LLC | 0 0.000% | -1,849,597 (Position Closed) | Filing History |
| 2025-11-14 1:10 pm Sale | 2025-09-30 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 0 0.000% | -1,370,938 (Position Closed) | Filing History |
| 2025-08-14 4:49 pm Purchase | 2025-06-30 | 13G | VYNE Therapeutics Inc. VYNE | Eventide Asset Management, LLC | 1,849,597 9.990% | 455,261 (+32.65%) | Filing History |
| 2025-08-14 3:04 pm Sale | 2025-06-30 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 1,370,938 8.230% | -478,652 (-25.88%) | Filing History |
| 2025-05-19 5:47 pm Purchase | 2025-03-31 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 1,849,590 9.990% | 1,849,590 (New Position) | Filing History |
| 2025-05-15 5:28 pm Sale | 2025-03-31 | 13G | VYNE Therapeutics Inc. VYNE | Citadel Advisors LLC | 1,100,329 7.200% | -80,815 (-6.84%) | Filing History |
| 2025-05-15 3:03 pm Unchanged | 2025-03-31 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-11-14 3:34 pm Sale | 2024-09-30 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 0 0.000% | -703,868 (Position Closed) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Citadel Advisors LLC | 1,181,144 8.500% | -23 (-0.00%) | Filing History |
| 2024-02-02 09:42 am Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 703,868 5.000% | -187,000 (-20.99%) | Filing History |
| 2023-11-13 4:41 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Citadel Advisors LLC | 1,181,167 8.500% | 1,181,167 (New Position) | Filing History |
| 2023-11-13 4:10 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Eventide Asset Management, LLC | 1,394,336 9.990% | 1,394,336 (New Position) | Filing History |
| 2023-11-13 4:03 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 1,394,336 9.990% | 1,394,336 (New Position) | Filing History |
| 2023-11-13 08:24 am Purchase | 2023-11-01 | 13D | VYNE Therapeutics Inc. VYNE | AI Biotechnology LLC | 3,201,980 19.990% | 3,201,980 (New Position) | Filing History |
| 2023-11-02 4:15 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 890,868 6.400% | 890,868 (New Position) | Filing History |
| 2022-02-14 7:33 pm Sale | 2021-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Perceptive Advisors LLC | 134,756 4.500% | -142,349 (-51.37%) | Filing History |
| 2021-08-25 5:04 pm Purchase | 2021-08-17 | 13G | VYNE Therapeutics Inc. VYNE | Perceptive Advisors LLC | 277,105 9.600% | 277,105 (New Position) | Filing History |
| 2021-07-09 6:05 pm Purchase | 2021-06-30 | 13G | VYNE Therapeutics Inc. VYNE | BlackRock Inc. BLK | 57,649 2.000% | 57,649 (New Position) | Filing History |
| 2021-02-16 4:13 pm Unchanged | 2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Great Point Partners, LLC | 0 0.000% | 0 (Unchanged) | Filing History |